SequelSEC

Armata Pharmaceuticals, Inc. ARMP

Biological Products, (No Diagnostic Substances) · CIK 0000921114 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$31.00K
Fiscal year ended 2020-06-30
Operating income
-$4.59M
Fiscal year ended 2020-06-30
Free cash flow
Unavailable
Fiscal year ended 2020-06-30

Valuation, from the filing

Public float$21.10MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.58Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio1.19x21th

Armata Pharmaceuticals, Inc. (ARMP) reported revenue of $31.00K and net income of -$4.71M for the fiscal year ended 2020-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Armata Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Armata Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-06-30
Revenue$31.00K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$4.59M
Net income-$4.71M
Research & developmentUnavailable
Weighted-average diluted sharesshares 18.35M
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPS$-0.26
Selling, general & administrativeUnavailable
General & administrative$1.97M
Selling & marketingUnavailable

Balance

Armata Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-06-30
Cash & equivalents$19.79M
Total assets$49.46M
Current assets$20.68M
Total liabilities$19.82M
Current liabilities$5.21M
Total equity incl. NCI$29.64M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
Goodwill$3.49M
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Armata Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-06-30
Operating cash flowUnavailable
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flowUnavailable
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Armata Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio3.97x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ARMP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.